Cardiology
Latest news
1101 articles · 20 / page
Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring
The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical
Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success
A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al
Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial
The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeu
Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk
The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent
GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra
FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial
The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physi
GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a
Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes
The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.
FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease
An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable wi
Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes
A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible
Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study
This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate
Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure
Evidence from the Myovasc study reveals that insulin resistance and C-peptide levels are independent predictors of impaired cardiac vagal activity in heart failure, suggesting that metabolic health directly influences autonomic regulation b
Bridging the Gap: Understanding In-Procedure Variability and Quality Control in the FAVOR III Europe QFR Analysis
The REPEAT-QFR study reveals a modest 72% diagnostic agreement between bedside and core-lab QFR. The findings underscore that angiographic quality and strict adherence to standard operating procedures are essential for accurate, non-invasiv
Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes
A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratifica
Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes
A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate’s protective effects remain consistent regardless of haptoglobin status, challenging pre
Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study
The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic ax
Beyond the Clock: How Circadian Rhythm and Life’s Essential 8 Shape Cardiovascular Longevity
Recent studies from the UK Biobank and Framingham Heart Study reveal that evening chronotypes face higher cardiovascular risks, largely mediated by poor adherence to the Life’s Essential 8 (LE8) health metrics, highlighting the critical rol
Type 1 Diabetes Confers Double the Risk of Coronary Stent Failure Compared to Non-Diabetics: A SWEDEHEART Analysis
A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a mor
Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management
The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduct
Browse by specialty
Open language-specific specialty feeds and department pages.